In patients with mostly undifferentiated pleomorphic sarcomas, 2-year DFS with the addition of preoperative and postoperative pembrolizumab (Keytruda) infusions reached 67%, as compared with 52% with ...
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family ...
LOS ANGELES – June 3, 2024 – For the last three decades, breakthroughs have been sparse for soft tissue sarcomas, which are rare cancers that affect muscles, fat and other connective tissues. Today, a ...
Against the backdrop of a case report, pembrolizumab was investigated as immunotherapy for undifferentiated pleomorphic soft tissue sarcoma. Noting that immunotherapy for soft tissue sarcoma (STS) has ...
(RTTNews) - Intensity Therapeutics, Inc. (INTS), a late-stage clinical biotechnology company focused on immune-based cancer therapies, announced Tuesday that its INVINCIBLE-3 Study has been authorized ...
After receiving a diagnosis of stage 3 sarcoma, one survivor proves that anything is possible. In 2014, Nicole Body was a pharmaceutical representative in Colorado and just married the love of her ...
Treatment with immunotherapy demonstrated positive results regarding survival in patients with two types of soft-tissue sarcomas, research found. Patients with certain sarcomas who received ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback